Financings

Arno Therapeutics Inc. closed a $12.7 million private placement of convertible debentures.

Lanthio Pharma BV raised $6.2 million in a Series A round to help it develop its LanthioPep platform.

Rexahn Pharmaceuticals Inc. priced a public offering to raise about $6.3 million.

Rib-X Pharmaceuticals Inc. completed a $67.5 million Series 2 preferred stock financing.

TxCell SA raised $16.1 million to fund a clinical study of its cell therapy in patients with Crohn's disease.

Deals

Ablynx NV and Algeta ASA entered a research collaboration for a targeted thorium conjugate.

Arena Pharmaceuticals Inc. signed an agreement with Ildong Pharmaceutical Co. Ltd. for temanogrel, Arena's inverse serotonin 2A receptor agonist.

Evolva Holding SA will acquire assets owned by Danish firm Fluxome Sciences A/S.

Northlake International LLC and Mundipharma International Corp. entered a collaboration to develop alkylating agents for the treatment of hematological malignancies.

Selecta Biosciences Inc. inked a potential $900 million deal with Sanofi SA to discover targeted, antigen-specific immunotherapies for food allergies.

Smith & Nephew plc acquired cell therapy company Healthpoint Biotherapeutics for $782 million in cash.

Tekmira Pharmaceuticals Corp. licensed RNAi payload technology from Marina Biotech Inc.

Unigene Laboratories Inc. and Tarix Pharmaceuticals Ltd. are developing TXA127, Tarix's lead drug.

VTU Technology and Minapharm Pharmaceuticals are collaborating to develop a human serum albumin (rHSA).

. . . And More

OxiGene Inc. received FDA orphan drug designation for OXi4503 in acute myelogenous leukemia.

Regeneron Pharmaceuticals Inc. received EU approval for Eylea (aflibercept) for wet AMD.

Senesco Technologies Inc. said its shares will be quoted on the OTCBB under the ticker symbol "SNTI."

Sucampo Pharmaceuticals Inc. launched Amitiza (lubiprostone), for chronic constipation, in Japan.

Viral Genetics Inc. changed its name to VG Life Science Inc. and conducted a 1-for-600 reverse stock split.